Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance

INCYTE CORP

2025-Q2 EPS reported $2.84 revenue$2,268,427,000

Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.
Jakafi net rev $764M (+8%); full-year guidance raised to $3.0-3.05B (prev $2.95-3.0B). Opzelura $164M (+35%).
Niktimvo launch strong with Q2 rev $36M; other oncology guidance raised to $500-520M (prev $415-455M).
New CEO Bill Meury appointed June 26, 2025 upon retirement of Hervé Hoppenot.
Novartis royalty dispute settled; Jakafi royalty rate reduced by 50% starting Jan 1, 2025; $280M paid in settlement.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.